New Zealand markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
286.36+16.94 (+6.29%)
At close: 4:00PM EDT
294.00 +7.64 (+2.67%)
Pre-market: 08:03AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close269.42
Open276.60
Bid293.51 x 1000
Ask0.00 x 1100
Day's range275.03 - 286.80
52-week range75.35 - 464.00
Volume2,558,793
Avg. volume4,197,172
Market cap69.447B
Beta (5Y monthly)-1.16
PE ratio (TTM)15.91
EPS (TTM)18.00
Earnings date09 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est327.99
  • Motley Fool

    Why BioNTech and RedHill Are Soaring This Week, While Novavax Is Sinking

    BioNTech (NASDAQ: BNTX) was up by 15.6% for the week as of the market close on Thursday, according to data from S&P Global Market Intelligence. Shares of Novavax (NASDAQ: NVAX), meanwhile, have lost 14.3%. BioNTech benefited from two positive developments.

  • Motley Fool

    Why BioNTech Stock Jumped Today

    What happened Shares of BioNTech (NASDAQ: BNTX) were jumping 5.5% higher as of 3:05 p.m. EDT on Thursday. The gain came after the company and its big partner, Pfizer (NYSE: PFE), announced efficacy of 95.

  • Business Wire

    Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine

    NEW YORK & MAINZ, Germany, October 21, 2021--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 years of age and older. In the trial, a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series restored vaccine protection against COVID